Pune, July 12, 2024 (GLOBE NEWSWIRE) -- The hormone replacement therapy (HRT) market is driven by factors such as the increasing prevalence of target diseases, along with the rising availability of long-acting hGH products. The American Thyroid Association estimates about 12.0% of the population in the United States would have thyroid disease in some form throughout their lives.
The majority of companies are joining the race to develop novel treatments, which is the reason why we're seeing new medical products launched so often. As an example, this included the European Commission granting marketing authorization to Ascendis Pharma for SKYTROFA in January 2022, which is indicated as a treatment for children and adolescents with growth hormone disorders. The product is the first weekly treatment for growth hormone deficiency in children and adolescents.
Hence, all these factors are skyrocketing the growth of the hormone replacement therapy market. In 2023, Based on product, the estrogen and progesterone replacement therapy segment held a maximum market share of 54.55%.
The dominance was explained by an increase in the number of women experiencing menopause. The American Congress of Obstetricians and Gynaecologists reports that daily, some 6,000 women in the U.S.
go into menopause. The parathyroid hormone replacement segment, by product, is expected to reach the fastest CAGR during the forecast period due to increasing incidence as well as rising product penetration. Approximat.